forecast glp-1 prescriptions growth 2025 semaglutide tirzepatide Agonists Weight Loss Drugs Market Report, 2025-2030 GLP-1 Market Trends and Global
Description
Strengths Acts via multiple pathways (GLP-1, AMPK, microbiome) Has existing human data showing reductions in fasting glucose, HbA1c, lipids Support receptor expression and islet health Limitations Low absorption and bioavailability Gastrointestinal discomfort is common (diarrhea, cramping)
Over 660,000 Californians received the drugs throughMedi-Cal in 2023.
Patients report feeling hot after retatrutide injections
Elevance Health Inc
Where expectations are low and outcomes dont have to be perfect a global mix across sectors, sizes, and narratives
Roughly 1 in 10 people carry a genetic variant that meaningfully blunts GLP-1 response
